Media Thread, page-10716

It’s like Groundhog Day here now with Azer-Cel CR as it was with the CF-33 acquisition & CR.

Now people are starting to understand as some results have come out from trials. The thing that got investors both times, is that we were well funded to complete trials - No CR needed. And then it came, but was each time for very good reason. I am what is considered a blue collar worker, I guess I have the added benefit of being able to understand the reasons why IMU have done these things at short notice. Because this space in Immuno-oncology is ever changing, there are technologies being developed that are not only synergistic, but may have been strategically necessary in the space, not only for our own IP, but also for the bargaining power with BP. When we were ANN’d about Oncarlytics it was stressed that IMU is not a CAR-T company, it’s complimentary to it. Now we are, allogenic at that. Why do you think that might be?

I am pretty fed up with all the BS on this board making PH out to be a greedy villian as well. If he didn’t have the nouse to dig out these amazing acquisitions & the contacts & trust to acquire them, there would be no IMU as we know it today. People can have pretty short memories…

Have a lovely day